CeriBell’s (CBLL) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research restated their buy rating on shares of CeriBell (NASDAQ:CBLL) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $30.00 price target on the stock.

A number of other equities analysts also recently commented on CBLL. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Raymond James Financial began coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group boosted their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.67.

CeriBell Trading Down 6.1%

CeriBell stock opened at $20.55 on Wednesday. CeriBell has a 12 month low of $10.01 and a 12 month high of $26.04. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The stock has a market cap of $762.41 million, a P/E ratio of -13.61 and a beta of 1.02. The company’s fifty day simple moving average is $20.60 and its 200-day simple moving average is $15.46.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. As a group, sell-side analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $21.49, for a total value of $537,250.00. Following the transaction, the director directly owned 772,652 shares in the company, valued at approximately $16,604,291.48. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Xingjuan Chao sold 79,000 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.27, for a total value of $1,680,330.00. Following the transaction, the chief executive officer directly owned 741,248 shares of the company’s stock, valued at $15,766,344.96. This represents a 9.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 375,212 shares of company stock worth $7,306,950 in the last ninety days. 20.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the last quarter. Yu Fan increased its position in CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the period. Novo Holdings A S raised its stake in CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after purchasing an additional 20,000 shares during the last quarter. TimesSquare Capital Management LLC boosted its holdings in CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after purchasing an additional 20,700 shares during the period. Finally, Millennium Management LLC grew its position in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after purchasing an additional 196,299 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.